Cargando…
Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging
OBJECTIVE: Recent availability of amyloid and tau positron emission tomography (PET) has provided us with a unique opportunity to measure the association of systemic vascular health with brain health after accounting for the impact of Alzheimer disease (AD) pathologies. We wanted to quantify early c...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282853/ https://www.ncbi.nlm.nih.gov/pubmed/30264411 http://dx.doi.org/10.1002/ana.25346 |
_version_ | 1783379079066550272 |
---|---|
author | Vemuri, Prashanthi Lesnick, Timothy G. Przybelski, Scott A. Graff‐Radford, Jonathan Reid, Robert I. Lowe, Val J. Zuk, Samantha M. Senjem, Matthew L. Schwarz, Christopher G. Gunter, Jeffrey L. Kantarci, Kejal Machulda, Mary M. Mielke, Michelle M. Petersen, Ronald C. Knopman, David S. Jack, Clifford R. |
author_facet | Vemuri, Prashanthi Lesnick, Timothy G. Przybelski, Scott A. Graff‐Radford, Jonathan Reid, Robert I. Lowe, Val J. Zuk, Samantha M. Senjem, Matthew L. Schwarz, Christopher G. Gunter, Jeffrey L. Kantarci, Kejal Machulda, Mary M. Mielke, Michelle M. Petersen, Ronald C. Knopman, David S. Jack, Clifford R. |
author_sort | Vemuri, Prashanthi |
collection | PubMed |
description | OBJECTIVE: Recent availability of amyloid and tau positron emission tomography (PET) has provided us with a unique opportunity to measure the association of systemic vascular health with brain health after accounting for the impact of Alzheimer disease (AD) pathologies. We wanted to quantify early cerebrovascular health–related magnetic resonance imaging brain measures (structure, perfusion, microstructural integrity) and evaluate their utility as a biomarker for cerebrovascular health. METHODS: We used 2 independent samples (discovery, n = 390; validation, n = 1,035) of individuals, aged ≥ 60 years, along the cognitive continuum with imaging from the population‐based sample of Mayo Clinic Study of Aging. We ascertained vascular health by summing up recently existing cardiovascular and metabolic conditions (CMC) from health care records (hypertension, hyperlipidemia, cardiac arrhythmias, coronary artery disease, congestive heart failure, diabetes mellitus, and stroke). Using multiple regression models, we quantified associations between CMC and brain health after accounting for age, sex, education/occupation, and AD burden (from amyloid and tau PET). RESULTS: Systemic vascular health was associated with medial temporal lobe thinning, widespread cerebral hypoperfusion, and loss of microstructural integrity in several white matter tracts including the corpus callosum and fornix. Further investigations suggested that microstructural integrity of the genu of the corpus callosum was suitable for assessing prodromal cerebrovascular health, had similar distributions in the discovery and independent validation datasets, and predicted cognitive performance above and beyond amyloid deposition. INTERPRETATION: Systemic vascular health has significant impact on brain structure and function. Quantifying prodromal cerebrovascular health–related brain measures that are independent of AD pathology–related changes has great utility for cognitive aging. Ann Neurol 2018;84:713–724 |
format | Online Article Text |
id | pubmed-6282853 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-62828532018-12-11 Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging Vemuri, Prashanthi Lesnick, Timothy G. Przybelski, Scott A. Graff‐Radford, Jonathan Reid, Robert I. Lowe, Val J. Zuk, Samantha M. Senjem, Matthew L. Schwarz, Christopher G. Gunter, Jeffrey L. Kantarci, Kejal Machulda, Mary M. Mielke, Michelle M. Petersen, Ronald C. Knopman, David S. Jack, Clifford R. Ann Neurol Research Articles OBJECTIVE: Recent availability of amyloid and tau positron emission tomography (PET) has provided us with a unique opportunity to measure the association of systemic vascular health with brain health after accounting for the impact of Alzheimer disease (AD) pathologies. We wanted to quantify early cerebrovascular health–related magnetic resonance imaging brain measures (structure, perfusion, microstructural integrity) and evaluate their utility as a biomarker for cerebrovascular health. METHODS: We used 2 independent samples (discovery, n = 390; validation, n = 1,035) of individuals, aged ≥ 60 years, along the cognitive continuum with imaging from the population‐based sample of Mayo Clinic Study of Aging. We ascertained vascular health by summing up recently existing cardiovascular and metabolic conditions (CMC) from health care records (hypertension, hyperlipidemia, cardiac arrhythmias, coronary artery disease, congestive heart failure, diabetes mellitus, and stroke). Using multiple regression models, we quantified associations between CMC and brain health after accounting for age, sex, education/occupation, and AD burden (from amyloid and tau PET). RESULTS: Systemic vascular health was associated with medial temporal lobe thinning, widespread cerebral hypoperfusion, and loss of microstructural integrity in several white matter tracts including the corpus callosum and fornix. Further investigations suggested that microstructural integrity of the genu of the corpus callosum was suitable for assessing prodromal cerebrovascular health, had similar distributions in the discovery and independent validation datasets, and predicted cognitive performance above and beyond amyloid deposition. INTERPRETATION: Systemic vascular health has significant impact on brain structure and function. Quantifying prodromal cerebrovascular health–related brain measures that are independent of AD pathology–related changes has great utility for cognitive aging. Ann Neurol 2018;84:713–724 John Wiley and Sons Inc. 2018-10-25 2018-11 /pmc/articles/PMC6282853/ /pubmed/30264411 http://dx.doi.org/10.1002/ana.25346 Text en © 2018 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Articles Vemuri, Prashanthi Lesnick, Timothy G. Przybelski, Scott A. Graff‐Radford, Jonathan Reid, Robert I. Lowe, Val J. Zuk, Samantha M. Senjem, Matthew L. Schwarz, Christopher G. Gunter, Jeffrey L. Kantarci, Kejal Machulda, Mary M. Mielke, Michelle M. Petersen, Ronald C. Knopman, David S. Jack, Clifford R. Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging |
title | Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging |
title_full | Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging |
title_fullStr | Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging |
title_full_unstemmed | Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging |
title_short | Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging |
title_sort | development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282853/ https://www.ncbi.nlm.nih.gov/pubmed/30264411 http://dx.doi.org/10.1002/ana.25346 |
work_keys_str_mv | AT vemuriprashanthi developmentofacerebrovascularmagneticresonanceimagingbiomarkerforcognitiveaging AT lesnicktimothyg developmentofacerebrovascularmagneticresonanceimagingbiomarkerforcognitiveaging AT przybelskiscotta developmentofacerebrovascularmagneticresonanceimagingbiomarkerforcognitiveaging AT graffradfordjonathan developmentofacerebrovascularmagneticresonanceimagingbiomarkerforcognitiveaging AT reidroberti developmentofacerebrovascularmagneticresonanceimagingbiomarkerforcognitiveaging AT lowevalj developmentofacerebrovascularmagneticresonanceimagingbiomarkerforcognitiveaging AT zuksamantham developmentofacerebrovascularmagneticresonanceimagingbiomarkerforcognitiveaging AT senjemmatthewl developmentofacerebrovascularmagneticresonanceimagingbiomarkerforcognitiveaging AT schwarzchristopherg developmentofacerebrovascularmagneticresonanceimagingbiomarkerforcognitiveaging AT gunterjeffreyl developmentofacerebrovascularmagneticresonanceimagingbiomarkerforcognitiveaging AT kantarcikejal developmentofacerebrovascularmagneticresonanceimagingbiomarkerforcognitiveaging AT machuldamarym developmentofacerebrovascularmagneticresonanceimagingbiomarkerforcognitiveaging AT mielkemichellem developmentofacerebrovascularmagneticresonanceimagingbiomarkerforcognitiveaging AT petersenronaldc developmentofacerebrovascularmagneticresonanceimagingbiomarkerforcognitiveaging AT knopmandavids developmentofacerebrovascularmagneticresonanceimagingbiomarkerforcognitiveaging AT jackcliffordr developmentofacerebrovascularmagneticresonanceimagingbiomarkerforcognitiveaging |